Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 284

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 284
---
 of common stock, which are referred to as Class A common stock and Class B common stock. Earnings and losses are shared pro rata between the two classes of shares. The Company has not considered the effect of the warrants sold in the IPO and the Private Placement to purchase an aggregate of of the Company’s Class A common stock in the calculation of diluted loss per share, since their exercise is contingent upon future events. As a result, diluted net loss per share of common stock is the same as basic net loss per share of common stock for the periods. Accretion of the carrying value of Class A common stock to redemption value is excluded from net loss per common stock because the redemption value approximates fair value. As of March 31, 2025 and March 31, 2024, the Company only had Class A common stock outstanding. The table below presents a reconciliation of the numerator and denominator used to compute basic and diluted net loss per share for the Class A common stock.

| ​                                                     
 ​                                                     
 ​                                                     
 Basic and diluted net loss per share:                 
 Numerator:                                            | ​ 
 ​ | ​                                    
 For the three months ended March 31, 
 2025                                 
 ​                                    
 ​                                    |         ​ | ​ 
 ​ | ​    
 2024 
 ​    
 ​    |         ​ |
|:------------------------------------------------------|:--|:-------------------------------------|----------:|:--|:-----|----------:|
| Net loss                                              | ​ | $                                    |  -891,382 | ​ | $    |  -858,231 |
| Denominator                                           | ​ |                                      |           | ​ |      |           |
| Basic and diluted weighted average shares outstanding | ​ |                                      | 7,055,859 | ​ |      | 7,275,074 |
| Basic and diluted net loss per share                  | ​ | $                                    |     -0.13 | ​ | $    |     -0.12 |

Income Taxes

The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes (“ASC 740”). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets

F-64

will not be realized